Aberrantly elevated STAT3 activity has been estimated to occur in >70% of human cancers [51] and can promote tumor cell proliferation, invasion, angiogenesis, and resistance to conventional chemotherapy, and radiation therapy.[52] To date, several STAT3 inhibitors have shown satisfactory therapeutic antitumor effects in preclinical studies and are in active clinical trials. The gene discussed is STAT3; the disease is neoplasm.